Sable Therapeutics Announces Licensing Agreement with Shanghai Liuqiang Medical Technology Co. for Development and Commercial Rights to its Fat Reducing SBL-003/SBL-004 Microneedle Patch in Greater China.

Posted on by

Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement for Greater China NEW YORK, April 25, 2023 /PRNewswire/ — Sable Therapeutics, an early stage biotechnology company developing novel therapies for fat reduction, today announced that it…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.